Hello, everyone, nice to see you again. We hope your weekend was restful and refreshing. Now, of course, the routine resumes and, for our part, that means brewing the mandatory cup of stimulation. Please join us as we peruse the news of the world and prepare for those meetings and deadlines. We hope your day goes well and do stay in touch...
Lilly Pays $300M For Avid Radiopharmaceuticals (Associated Press)
Sanofi Asks Genzyme To Let Investors Decide (Reuters)
Pfizer Rheumatoid Arthritis Drug Met Late-Stage Study Goal (Bloomberg News)
Teva Concedes A Generic Advair Is Unlikely (Reuters)
Quintiles And Its Successful, But Controversial Strategy (Forbes)
Docs Suggest Using Fewer Bisphosphonates (Los Angeles Times)
Bayer Implements A New Branding Strategy (PharmaTimes)
ZymoGenetics CEO Leaves Now That Merger Is Complete (Xconomy)
Athersys & Pfizer Move Stem Cell Therapy To Mid-Stage (Dow Jones)
Maine Pine Needles Contain Needed Tamiflu Material (Associated Press)
2 Comments
Millions of Christmas trees are discarded within a month after the holiday. If Roche is interested, let them foot the bill for a nationwide roundup of used triees to get their Tamiflu instead of deforesting the beattiful pine forests of Maine. The state is in economic trouble, but they can improve their lot by regulating the lobster price manipulators driving down the price of lobster rather than cutting more trees.
This isn't quite McDonalds deforestation of the Amazon. There are no chain saws buzzing for pine needles for Tamiflu - this concept is still in the laboratory. Ikea already collects used Christmas trees - Roche needs a JV...